CytoMed Therapeutics Limited is classed by the SEC under Pharmaceutical Preparations (industry code 2834), based in 1 Commonwealth Lane, SG. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $252 thousand and a loss of $3 million (its filed statements).
Pre-revenue companyPharmaceutical Preparations1 Commonwealth Lane, SGfilings since 20214 of 9 filed, 5 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2834), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.4 out of ten, 4 of 9 metrics filed and 5 estimated: past 5.6 out of ten, present 5.8 out of ten, future 5.0 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 8.2 out of ten. No warning events in its filings since 2021. 82nd percentile among 497 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 325 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Shareholder treatment (past): 4.6 out of ten. CrossAssetData estimate 4.6/10, confidence 35 of 100 (one part). 46th percentile among 463 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 7.0 out of ten. ROE -58%: lost 58¢ per shareholder dollar. Leverage 14%: owes 14¢ per asset dollar. 70th percentile among 472 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.5 out of ten. bottom 45% of 314 in its family; net margin -1232%. 45th percentile among 314 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 371 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Room to expand (future): 4.8 out of ten. bottom 48% of 272 in its family for room to expand. 48th percentile among 272 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 5.0 out of ten. CrossAssetData estimate 5.0/10, confidence 20 of 100 (family median). 50th percentile among 308 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Expectations vs reality (future): 5.3 out of ten. CrossAssetData estimate 5.3/10, confidence 20 of 100 (family median). 50th percentile among 235 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 20-F filed 2026-03-31 for the period ended 2025-12-31 (on EDGAR). Newest filing: Form 6-K, 2026-09-30. Filings on record since 2021. Read from EDGAR 2026-10-12.
Who runs it
Goh, Yvonne (Chief Financial Officer); Tan, Yoong Ying (Chief Corporate Officer); Choo, Chee Kong (director); Toh, Keng Kiat (director); Leong, Mark Kei Wei (director); Yew, Chak Hua (director). 6 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.